You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Evaluation of a new class of molecules for treating MRSA infective endocarditis
SBC: AGILE SCIENCES, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Patients with infective endocarditis (IE) have a poor prognosis with one third of the patients succumbing to the infection within the first year. Treatments for endocarditis involve antibiotic therapy and/or surgery that cost upwards of 100,000 per patient; however, many cases do not respond to the antibiotic treatment and surgery poses high risks. Cases of en ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Targeting c-Myc and Akt with PP2A reactivation therapy for the treatment of breas
SBC: ONCOTIDE PHARMACEUTICALS, INC. Topic: NCIDESCRIPTION (provided by applicant): Each year in the United States over 270,000 women will be diagnosed with breast cancer and over 40,000 will die from the disease. While multiple forms of breast cancer exist, a common theme in most of the forms involvesaberrations in signal transduction pathways that lead to inhibition of the programmed cell death process known as apoptosis. Apoptosis is a care ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Proteomic differentiation of leukemia cells based on multiplexed arrays and mass
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: NIGMSDESCRIPTION (provided by applicant): Although some gene mutations can predict response to certain targeted therapies, single-gene testing has limits. Multiple important signaling pathways that may be the causes of human malignancy have continuously been discovered and dissected. Pathway and network diagnostic tests are challenging but are clearly on the way. Through this NIH STTR Phase I study, we ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Osteochondral tissue repair in an ovine model using a 3D woven poly (e-caprolacto
SBC: Cytex Therapeutics, Inc. Topic: NIADESCRIPTION (provided by applicant): Standard microfracture is a first-line, widely used and cost-effective surgical technique for repairing damaged articular cartilage, but, it is limited by decreased long-term efficacy and limited applicability in largerlesions. This leads to a burgeoning economic burden associated with primary and follow-up treatment costs, estimated at more than 40 billion dol ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Controlling mechanical signal transduction to treat osteoarthritis
SBC: Cytex Therapeutics, Inc. Topic: NIADESCRIPTION (provided by applicant): Controlling mechanical signal transduction to treat osteoarthritis Abstract The TRPV4 calcium (Ca++) permeable ion channel has been shown to be expressed and functional in chondrocytes, the cells responsible for the maintenance of cartilage in weight-bearing joints. Trauma of joints with subsequent damage of cartilage, as well as chronically increased joint loa ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Identification of potent and selective GLI1 inhibitors
SBC: Zen-Bio, Inc. Topic: NCIDESCRIPTION (provided by applicant): Characterization of human tumor samples and cell lines in combination with inhibitor studies in animal models has established a central role for the Hh pathway in a vast array of cancer types, including small-cell lung, pancreatic, oesophageal, prostate, breast, colon, liver and ovarian cancers. Hh signaling is now implicated in approximately 20-25% of all can ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Medical Images, HTML5, and Clinical Trial Remote Collaboration
SBC: HEART IMAGING TECHNOLOGIES, LLC Topic: NHLBIDESCRIPTION (provided by applicant): Medical drugs and devices are regulated by the U.S. Food and Drug Administration (FDA) based on data from multicenter clinical trials. In 2010, U.S. spending on clinical trials was approximately 25 billion. Over the past decade the efficiency of clinical trials has been improved by electronic data capture (EDC) systems, whose use has increased from 38% to 61% ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Urinary Biomarkers of Renal Mitochondrial Dysfunction
SBC: SCHNELLGEN, INC. Topic: NIEHSDESCRIPTION (provided by applicant): The long-term goal of this project is to identify and validate biomarkers of mitochondrial dysfunction due to environmental stressors. Diverse acute insults from surgery, trauma, ischemia/reperfusion (I/R) and drug andenvironmental chemical toxicity lead to mitochondrial dysfunction and result in cell injury and death in many organs/tissues (e.g. heart, lung, b ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of
SBC: AARDEN PHARMACEUTICALS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of tuberculosis Aarden Pharmaceuticals Project Summary/Abstract The need exists for a new, breakthrough therapeutic for tuberculosis (TB). Current treatment regimens with toxic chemotherapeutic drugs are too long, causing poor compliance which results in reduced efficacy and the emer ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
STTR Phase I: Novel Molecularly Targeted Tracer for Specific and Sensitive Imaging of Cancer
SBC: CLAVE BIODESIGN, INC Topic: EBThis Small Business Technology Transfer Phase I project takes an innovative approach at tumor targeting by investigating an entirely novel tumor targeting platform that utilizes bone marrow derived, circulating tumor homing cells as natural vectors. Through screening of phage display peptide libraries we have identified high affinity peptide ligands that bind these cells with high specificity. The ...
STTR Phase I 2013 National Science Foundation